CADL News - Candlesense

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

(NASDAQ:CADL) NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing...

Appointments

9 days ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal bio...

Investor events

14 days ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal bio...

Are there any macro‑economic or sector‑specific trends (e.g., biotech funding environment, cancer‑therapy market demand) that could amplify or mitigate the impact of this release on CADL's stock? What is the current short‑interest level on CADL, and could the news trigger short covering or increased short‑selling activity? How does the sentiment score of 10 align with market expectations, and could this indicate a potential over‑ or under‑reaction in the stock price?

Earnings

28 days ago